Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELY trial of regorafenib with circulating tumor DNA monitoring in pretreated unresectable colorectal cancer
2014-004927-27Phase 2Completed
- Sponsor
- Medical University of Vienna, Department of Internal Medicine I
- Start
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of regorafenib in colorectal cancer (CRC), sponsored by Medical University of Vienna, Department of Internal Medicine I. Started Nov 2014; status: completed.
02
Drugs
regorafenib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2014-004927-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004927-27.